ClinicalTrials.gg
RecruitingNCT04141462EX²TRICANUpdated Apr 3, 2026

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

An interventional study of blood sample in Cancer and Genetic Predisposition, sponsored by Centre Georges Francois Leclerc. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Centre Georges Francois Leclerc · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
613
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

Read the detailed description

The main objective of this study is to evaluate the interest of the SHD-E approaches after a negative result of the analysis called " gene panel " tested in routine in order to identify a genetic factor of predisposition to the cancer.

02

Conditions studied

  • Cancer
  • Genetic Predisposition

Keywords

  • genetic mutations
  • early sporadic or familial cancer
  • gene panel
  • exome analysis
  • high-throughput exome sequencing
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 613 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Georges Francois Leclerc is the lead sponsor of 75 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Index case:

  1. Major or minor patient
  2. Histological or cytological evidence of malignant tumor diagnosis
  3. Patient with cancer before age 40 (or before age 30 for breast cancer).
  4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned
  5. Patient affiliated to a social security scheme
  6. Signature of EXTRICAN
  7. Availability of a tumor sample if needed secondary functional studies
  8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)
  9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)

Related:

  1. Major or minor patient
  2. Histological or cytological evidence of the diagnosis of malignant tumor if
  3. Patient affiliated to a social security scheme
  4. Signing informed consent EXTRICAN

Exclusion criteria

Exclusion Criteria:

Index and related case:

  1. Refusal of the patient participation
  2. Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study
  3. Patient under guardianship, curatorship or safeguard of justice
  4. Pregnant woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
613 participants (estimated)

Study arms

  • Experimental
    Patients with a a constitutional genetic alteration

    one genetic consultation and one blood test

    Genetic: blood sample

Interventions

  • Geneticblood sample

    blood test

06

What researchers measure

Primary outcomes

  1. genetic mutations

    SHD-E analysis

    Time frame: inclusion

07

Study locations

1 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Apr 2028, 102 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 102 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Oct 28, 2019
StartActual
Oct 7, 2019
Primary completionEst.
Apr 7, 2028
CompletionEst.
Apr 7, 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04141462
Lead sponsor
Centre Georges Francois Leclerc
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Oct 7, 2019
Primary completion
Apr 7, 2028 (estimated)
Completion
Apr 7, 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Sophie NAMBOT, Dr
Contact
sophie.nambot@chu-dijon.fr
03 80 29 53 13
Emilie REDERSTORFF
Contact
erederstorff@cgfl.fr
03 45 34 81 16

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion